|
Press Releases |
|
 |
|
Thursday, July 9, 2020 |
|
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease |
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease. more info >> |
|
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma |
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA. more info >> |
|
Wednesday, July 8, 2020 |
|
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong |
Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health. more info >> |
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma |
Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide (generic name, development code: E7438, "tazemetostat") for EZH2 gene mutation-positive follicular lymphoma. more info >> |
|
Monday, July 6, 2020 |
|
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan |
Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020. more info >> |
|
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan |
Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020. more info >> |
|
Wednesday, July 1, 2020 |
|
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID |
The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai announced today that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. more info >> |
|
Thursday, June 25, 2020 |
|
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea |
Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide"). more info >> |
|
Wednesday, June 10, 2020 |
|
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa |
Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel coronavirus infection in Africa, beginning with the activities described below. more info >> |
|
Thursday, June 4, 2020 |
|
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons |
Eisai Co., Ltd. announced today that the digital tool for self-assessment of brain performance (brain health) "NouKNOWTM", which Eisai has launched in Japan, is to be expanded in the fixed-rate membership beauty salon "Attina", which is operated by Youforio Co., Ltd. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Champion REIT Presents 'Lupus Reimagined' Art Exhibition, Connecting Community Through Art
Jun 6, 2025 18:55 HKT/SGT
|
|
|
International Consortium Rolls Out Major EV Battery Swapping Initiative in Tokyo
Jun 6, 2025 16:42 JST
|
|
|
Tredu.com Launches Global Platform to Revolutionize Trading Education
Jun 6, 2025 15:40 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Receives 2025 Technology Award from Catalyst Manufacturers Association, Japan, for Development and Practical Application of Electrode Catalysts for PEM Water Electrolysis
Jun 6, 2025 11:00 JST
|
|
|
Fujitsu unveils Technology and Service Vision 2025: People-AI collaboration for a net positive future
Jun 6, 2025 10:44 JST
|
|
|
Latest Firewall Vulnerability Reinforces Need for Post-Breach Privileged Access Controls - TACACS.net Offers a Critical Layer
Jun 6, 2025 04:30 HKT/SGT
|
|
|
Naoris Protocol Expands into the Nordics with Strategic Consulting Hub in Oslo
Jun 5, 2025 21:00 HKT/SGT
|
|
|
PlayX Showcases AI-Powered Transparency and Fairness at SiGMA Asia 2025 in Manila
Jun 5, 2025 17:00 HKT/SGT
|
|
|
The Generation Essentials Group and Black Spade Acquisition II Co Complete Business Combination
Jun 5, 2025 11:33 HKT/SGT
|
|
|
Global Communities Unite at centralwOrld as Thailand Steps Forward on Global LGBTQ+ Stage with Central Pattana's Pride For All
Jun 5, 2025 08:30 HKT/SGT
|
|
|
TF International Facilitates Hong Kong's Successful Issuance of First Central Asian Sovereign Bond
Jun 4, 2025 22:28 HKT/SGT
|
|
|
Alpha Growth plc: Alpha Alternative Assets Fund Update ("AAAF")
Jun 4, 2025 15:00 JST
|
|
|
MHI Thermal Systems Receives A' Design Awards
Jun 4, 2025 14:10 JST
|
|
|
CBL International Limited Announces Share Repurchase Program
Jun 4, 2025 12:00 HKT/SGT
|
|
|
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Jun 4, 2025 12:58 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|